Cutaneous Myelofibrosis With JAK2 V617F Mutation: Metastasis, Not Merely Extramedullary Hematopoiesis!

被引：11
|
作者：
Fraga, Garth R. [1 ]
Caughron, Samuel K. [2 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA
[2] MAWD Pathol Grp, Kansas City, MO USA
来源：
AMERICAN JOURNAL OF DERMATOPATHOLOGY | 2010年 / 32卷 / 07期
关键词：
myelofibrosis; extramedullary hematopoiesis; metastasis; JAK2; leukemia; MYELOID METAPLASIA; IDIOPATHIC MYELOFIBROSIS; SKIN; MANIFESTATION; PATHOGENESIS;
D O I：
10.1097/DAD.0b013e3181d3ca2f
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm. There are 31 reported cases of cutaneous involvement by PMF, most of which have been described as "extramedullary hematopoiesis.'' We report a new case of cutaneous involvement by PMF and demonstrate mutation of the Janus kinase 2 gene in the cutaneous lesions. Extramedullary myelofibrosis is best considered a metastatic phenomenon. Reporting such cases as extramedullary hematopoiesis may cause confusion with reactive forms of extramedullary hematopoiesis.
引用
收藏
页码：727 / 730
页数：4
相关论文
共 50 条
  • [41] Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia
    Monika Ribeiro Mello de Conchon
    Juliana Lima Costa
    Mafalda Megumi Yoshinaga Novaes
    Pedro Enrique Dorlhiac-Llacer
    Dalton de Alencar Fischer Chamone
    Israel Bendit
    International Journal of Hematology, 2008, 88 : 243 - 245
  • [42] Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis
    Nedumannil, Rithin
    Karmi, Tal
    Blombery, Piers
    Szer, Jeff
    Ritchie, David S.
    Chee, Lynette C. Y.
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, : 1160 - 1164
  • [43] Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation
    Thomas Meyer
    Volker Ruppert
    Christian Görg
    Andreas Neubauer
    International Journal of Hematology, 2010, 91 : 117 - 120
  • [44] Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
    Abdelghani, Maroua
    Hammami, Haifa
    Zidi, Wiem
    Amouri, Hassiba
    Othmen, Hind Ben Hadj
    Farrah, Ahlem
    Menif, Samia
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (08)
  • [45] Usefulness of Real-time Semi-quantitative PCR, JAK2 MutaScreen™ Kit for JAK2 V617F Screening
    Chae, Hyojin
    Lee, Je-Hoon
    Lim, Jihyang
    Jung, Seung-Won
    Kim, Myungshin
    Kim, Yonggoo
    Han, Kyungja
    Cho, Byoung-Sik
    Cho, Seok-Goo
    Lee, Jong-Wook
    Min, Woo-Sung
    KOREAN JOURNAL OF LABORATORY MEDICINE, 2009, 29 (03): : 243 - 248
  • [46] Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia
    Dahabreh, Issa J.
    Zoi, Katerina
    Giannouli, Stavroula
    Zoi, Christine
    Loukopoulos, Dirnitrios
    Voulgarelis, Michael
    LEUKEMIA RESEARCH, 2009, 33 (01) : 67 - 73
  • [47] JAK2 V617F/C618R mutation in a patient with polycythemia vera: A case study and review of the literature
    Yoo, Jong-Ha
    Park, Tae Sung
    Maeng, Ho-Young
    Sun, Young-Kyu
    Kim, Young-Ah
    Kie, Jeong-Hae
    Cho, Eun Hae
    Song, Jaewoo
    Lee, Kyung-A
    Suh, Borum
    Choi, Jong Rak
    CANCER GENETICS AND CYTOGENETICS, 2009, 189 (01) : 43 - 47
  • [48] JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    Tefferi, A.
    Lasho, T. L.
    Patnaik, M. M.
    Finke, C. M.
    Hussein, K.
    Hogan, W. J.
    Elliott, M. A.
    Litzow, M. R.
    Hanson, C. A.
    Pardanani, A.
    LEUKEMIA, 2010, 24 (01) : 105 - 109
  • [49] JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    A Tefferi
    T L Lasho
    M M Patnaik
    C M Finke
    K Hussein
    W J Hogan
    M A Elliott
    M R Litzow
    C A Hanson
    A Pardanani
    Leukemia, 2010, 24 : 105 - 109
  • [50] Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis
    Konoplev, Sergej
    Hsieh, Pin-Pen
    Chang, Chung-Che
    Medeiros, L. Jeffrey
    Lin, Pei
    HUMAN PATHOLOGY, 2007, 38 (12) : 1760 - 1763
12345